Increasing immunogenicity of cancer vaccines to improve their clinical outcome

Expert Review of Vaccines

Volumn 12, Issue 10, 2013, Pages 1111-1113

  Parmiani, Giorgio ^a   Cimminiello, Carolina ^a   MacCalli, Cristina ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

cancer vaccines; immunogenicity; T cells; tumor antigens

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2; IPILIMUMAB; MELANOMA VACCINE; MITOMYCIN; ONCOLYTIC VIRUS; OXALIPLATIN; PEPTIDE VACCINE;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CELL DEATH; DENDRITIC CELL; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; METASTATIC MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR CELL DESTRUCTION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84886038035     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.839274     Document Type: Review

References (22)

1. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev. Vaccines 12(10), 1155-1172.
2. Saccheri F, Pozzi C, Avogadri F et al. Bacteria-induced gap junctions in tumors favour antigen cross-presentation and antitumor immunity. Sci. Transl. Med. 2, 44ra57 (2010).
3. Vacchelli E, Senovilla L, Eggermont A et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2(3), e23510 (2013).
4. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunther. 54, 187-207 (2005). (Pubitemid 40174238)
5. Chauchet X, Wang Y, Polack B, Toussaint B, Le Gouellec A. Live attenuated bacteria as a cancer vaccine vector. Expert Rev. Vaccines 12(10), xxxx-xxxx.
6. Bracci L, Capone I, Moschella F, Proietti E Belardelli F. Exploiting dendritic cells in the development of cancer vaccines. Expert Rev. Vaccines 12(10), 1195-1210.
7. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex-vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007). (Pubitemid 47480309)
8. Fridman WH, Pagès F, Sautés-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
9. Ungaro F, Conte C, Quaglia F, Tornesello ML, Buonaguro FM, Buonaguro L. VLPs and particle strategies for cancer vaccines. Expert Rev. Vaccines 12(10), 1173-1193.
10. Parmiani G, DiFilippo A, Novellino L, Castelli C. Unique tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178, 1975-1979 (2007). (Pubitemid 46233392)
11. Rammensee HG, Singh-Jasuja H. HLA-ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev. Vaccines 12(10), 1211-1217.
12. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012).
13. Haen SP, Rammensee H-G. The repertoire of human tumor-associated epitopes identification and selection of antigens and their application in clinical trials. Curr. Opin. Immunol. 25, 277-283 (2013).
14. Aurisicchio L, Mancini R, Ciliberto G. Cancer vaccination by electro-gene-transfer. Expert Rev. Vaccines 12(10), 1127-1137.
15. Impellizeri JA, Ciliberto G, Aurisicchio L. Electro-gene-transfer as a new tool for cancer immunotherapy in animals. Vet. Comp. Oncol. doi:10.1111/vco.12006 (2012) (Epub ahead of print).
16. Senovilla L, Vacchetti E, Garcia P et al. Trial watch. DNA vaccines for cancer therapy. Oncoimmunology 2, 4 e23803 (2013).
17. Berzofsky JA, Wood LV, Terabe M. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Rev. Vaccines 12(10), 1115-1118.
18. Eggermont A, Robert C. New drugs in melanoma: It's a whole new world. Eur. J. Cancer 47, 2150-2157 (2011).
19. Topalian SL, Sznol M, Brahmer JR et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. J. Clin. Oncol. 31(Suppl.), Abstract 3002 (2013).
20. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J. Med. 363, 411-422 (2010).
21. Schwartzentruber D, Lawson DH, Richards JM et al. Gp100 peptide vaccine andd interleukin-2 in patients with advanced melanoma. N. Engl J. Med. 364, 2119-2127 (2011).
22. Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induced market T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394 (2011).